Hospital Injectable Products · LP-175
Ampicillin Powder for injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-175Hospital Injectable Products
- Generic identity
- AmpicillinPowder for injection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-175
- Generic ingredient
- Ampicillin
- Dosage form
- Powder for injection
- Proposed strength
- 500 mg vial; 1 g vial
- Proposed pack
- Vial; carton 10 vials
- Portfolio category
- Hospital Injectable Products
About Ampicillin
Ampicillin is a penicillin-class antibiotic that inhibits bacterial cell-wall synthesis. The injectable form is used in selected bacterial infections when a parenteral route is appropriate. It does not treat viral illness and is not suitable for every organism or infection site. Choice requires the clinical diagnosis, likely pathogens, local resistance and the patient’s allergy history.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Professional care considers severity, infection site, microbiological findings and the need for source control. When possible, culture results help refine therapy and avoid unnecessary broad or prolonged treatment. Injectable ampicillin can be used in hospital or other supervised settings under applicable guidance. The listed vial strengths do not establish a regimen, a neonatal indication, combination therapy or a candidate-specific approved infection list.
Important safety considerations
Penicillin hypersensitivity can cause anaphylaxis or serious skin reactions. Diarrhoea may reflect antibiotic-associated colitis and requires assessment when severe, persistent or bloody. Kidney function and exposure can influence toxicity, including neurological effects in susceptible patients. Review previous reactions to beta-lactam antibiotics and concurrent medicines. A non-specific past rash should be assessed accurately, while a history of a severe reaction must not be ignored.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source lists powder for injection in vials. Reconstitution diluent, final concentration, route, sodium contribution and usable period after preparation require the exact authorized label. These characteristics cannot be transferred from a different vial or manufacturer.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review diagnosis, cultures, susceptibility, allergy history and kidney function. Confirm the precise vial and supervised preparation requirements within local antimicrobial guidance.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Ampicillin
- Dosage form / presentation
- Powder for injection
- Catalogue strength
- 500 mg vial; 1 g vial
- Catalogue pack
- Vial; carton 10 vials
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- The catalogue establishes ampicillin powder for injection in 500 mg and 1 g vials but does not identify the exact salt, authorised route, reconstitution diluent, final concentration or post-reconstitution stability.
- Each vial strength requires its own controlled preparation and pack specification; external instructions from another manufacturer are not transferred.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Ampicillin Injectiongovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming exact active chemical form, concentration or vial content, container/fill, authorised route(s), excipients/preservatives and preparation/compatibility controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-175, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-175.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.